Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

In the ongoing battle against COVID-19, the United States has leaned heavily on vaccines as its primary weapon. While vaccination has been a cornerstone of the country’s public health strategy, it's ...

Researchers are increasingly developing antibody therapies to treat infectious diseases. Therapies are being designed to ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Professor Ruby Hoo Lai-chong (first, right), Department of Pharmacology and Pharmacy of HKUMed, and her research team have successfully developed a neutralising monoclonal antibody, 6H2, which targets ...

In this video, Jeremy Faust, MD, editor-in-chief of MedPage Today, looks at the rise and fall of monoclonal antibodies for COVID-19, and discusses the population most affected by the FDA's reversal of ...

The diversity of development tools, an abundance of manufacturing options, and standardization of many unit operations has ushered in a golden age for monoclonal antibodies (mAbs). mAb process ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

Monoclonal antibodies (mAbs) have revolutionized cancer therapy due to their ability to specifically target tumor cells while sparing healthy ones. These biologics have become indispensable in ...

CounterX Therapeutics, Inc., a biotechnology company focused on developing novel antibody therapeutics and vaccines to address opioid overdose and dependence, today announced the publication of its ...